Cancer Anorexia-Cachexia Syndrome: Current Issues in

Ca-A Cancer Journal for Clinicians 52, 72-91 DOI: 10.3322/canjclin.52.2.72

Citation Report

#	Article	IF	Citations
1	Emesis, appetite, and endocannabinoids. Gastroenterology, 2002, 123, 655.	0.6	3
2	Orexin reverses cholecystokinin-induced reduction in feeding. Diabetes, Obesity and Metabolism, 2002, 4, 399-401.	2.2	17
3	Nutrition and head and neck cancer. Current Oncology Reports, 2003, 5, 158-163.	1.8	12
4	Central nervous determination of food storage—a daily switch from conservation to expenditure: implications for the metabolic syndrome. European Journal of Pharmacology, 2003, 480, 51-65.	1.7	20
5	Skeletal muscle metabolism in physiology and in cancer disease. Journal of Cellular Biochemistry, 2003, 90, 170-186.	1.2	61
6	Melanocortin Signaling and Anorexia in Chronic Disease States. Annals of the New York Academy of Sciences, 2003, 994, 275-281.	1.8	39
7	Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology, 2003, 124, 1325-1336.	0.6	305
8	Cancer cachexia. Molecular Cancer, 2003, 2, 36.	7.9	54
9	Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncology, The, 2003, 4, 686-694.	5.1	200
10	Paraneoplastic Syndromes Involving the Nervous System. New England Journal of Medicine, 2003, 349, 1543-1554.	13.9	912
11	Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut, 2003, 52, 947-952.	6.1	419
12	Anorexia and Weight Loss in Older Persons. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2003, 58, M131-M137.	1.7	128
13	Low Circulating IGF-II Concentrations Predict Weight Gain and Obesity in Humans. Diabetes, 2003, 52, 1403-1408.	0.3	86
14	Title is missing!. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 421-426.	1.3	3
15	Title is missing!. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 395-399.	1.3	4
16	Improving food intake in anorectic cancer patients. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 421-426.	1.3	15
17	Cachexia and obesity: two sides of one coin?. Current Opinion in Clinical Nutrition and Metabolic Care, 2003, 6, 395-399.	1.3	30
18	Appetite and Cancer-Associated Anorexia: A Review. Journal of Clinical Oncology, 2004, 22, 1510-1517.	0.8	123

ATION REDO

#	Article	IF	CITATIONS
19	Serum levels of leptin and proinflammatory cytokines in patients with gastrointestinal cancer. International Journal of Clinical Practice, 2004, 58, 545-549.	0.8	40
20	Oleylethanolamide: a lipid mediator involved in gut satiety mechanisms. Journal of Gastroenterology and Hepatology (Australia), 2004, 19, 117-117.	1.4	2
21	Effects of lipopolysaccharide treatment on feeding of goldfish: role of appetite-regulating peptides. Brain Research, 2004, 998, 139-147.	1.1	44
22	Fish Oil Supplementation in the Treatment of Cachexia in Pancreatic Cancer Patients. International Journal of Gastrointestinal Cancer, 2004, 34, 143-150.	0.4	21
23	Adipose tissue in Walker 256 tumour-induced cachexia: possible association between decreased leptin concentration and mononuclear cell infiltration. Cell and Tissue Research, 2004, 318, 503-514.	1.5	52
24	Dietary interventions in cancer. Clinical and Translational Oncology, 2004, 6, 496-500.	1.2	2
25	Utilization of comprehensive geriatric assessment in cancer patients. Critical Reviews in Oncology/Hematology, 2004, 49, 53-67.	2.0	50
26	Nutritional status and cytokine-related protein breakdown in elderly patients with gastrointestinal malignancies. Journal of Surgical Oncology, 2004, 86, 91-98.	0.8	18
27	Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2136-2141.	1.8	65
28	4-{(2R)-[3-Aminopropionylamido]-3-(2,4-dichlorophenyl)propionyl}-1-{2-[(2-thienyl)ethylaminomethyl]phenyl}pip as a Potent and Selective Melanocortin-4 Receptor AntagonistDesign, Synthesis, and Characterization. Journal of Medicinal Chemistry, 2004, 47, 6821-6830.	oerazine 2.9	34
29	Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB Journal, 2004, 18, 439-456.	0.2	366
30	The use of nutraceuticals in cancer therapy. Veterinary Clinics of North America - Small Animal Practice, 2004, 34, 249-269.	0.5	26
31	Interleukin-1?? system in anorectic catabolic tumor-bearing rats. Current Opinion in Clinical Nutrition and Metabolic Care, 2004, 7, 419-426.	1.3	44
32	Therapy of muscle wasting in cancer: what is the future?. Current Opinion in Clinical Nutrition and Metabolic Care, 2004, 7, 459-466.	1.3	38
33	Insights Into Novel Biological Mediators of Clinical Manifestations in Cancer. AACN Advanced Critical Care, 2004, 15, 112-118.	1.9	4
34	Body Compositional Changes in Cancer Cachexia. Topics in Clinical Nutrition, 2004, 19, 85-94.	0.2	6
35	Catabolic outcome from non-gastrointestinal malignancy-related malabsorption leading to malnutrition and weight loss. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 419-427.	1.3	5
36	Endocannabinoids and Food Intake: Newborn Suckling and Appetite Regulation in Adulthood. Experimental Biology and Medicine, 2005, 230, 225-234.	1.1	94

#	Article	IF	CITATIONS
37	Eating Problems and Weight Loss for Patients With Head and Neck Cancer. Cancer Nursing, 2005, 28, 425-435.	0.7	122
38	Optimization of piperazinebenzylamines with a N-(1-methoxy-2-propyl) side chain as potent and selective antagonists of the human melanocortin-4 receptor. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4615-4618.	1.0	13
39	Potent and orally active non-peptide antagonists of the human melanocortin-4 receptor based on a series of trans-2-disubstituted cyclohexylpiperazines. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 4389-4395.	1.0	33
40	What's New in Otolaryngology—Head and Neck Surgery. Journal of the American College of Surgeons, 2005, 201, 101-109.	0.2	1
41	Malnutrition in Hemodialysis Patients: What Therapy?. American Journal of Kidney Diseases, 2005, 46, 371-386.	2.1	97
42	Quality of life as predictor of weight loss in patients with head and neck cancer. Head and Neck, 2005, 27, 302-310.	0.9	83
43	Outcome research in palliative care: could it represent a new dimension of clinical research or clinical practice?. Supportive Care in Cancer, 2005, 13, 176-181.	1.0	8
44	Cancer cachexia modifies the zonal distribution of lipid metabolism-related proteins in rat liver. Cell and Tissue Research, 2005, 321, 419-427.	1.5	18
45	Management of common symptoms of advanced lung cancer. Current Treatment Options in Oncology, 2005, 6, 61-68.	1.3	3
46	Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut, 2005, 54, 18-24.	6.1	414
47	Leptin and Neuropeptide Y Plasma Levels in Children with Cancer. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 485-9.	0.4	6
48	Prognostic Role of Interleukin-1β Gene and Interleukin-1 Receptor Antagonist Gene Polymorphisms in Patients With Advanced Gastric Cancer. Journal of Clinical Oncology, 2005, 23, 2339-2345.	0.8	56
49	Cancer cachexia. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 779-788.	0.2	97
50	Tratamiento de los sÃntomas generales y cuidados básicos. FMC Formacion Medica Continuada En Atencion Primaria, 2005, 12, 14-22.	0.0	1
51	Common Symptoms in Advanced Cancer. Surgical Clinics of North America, 2005, 85, 237-255.	0.5	32
52	The Science of Megestrol Acetate Delivery. BioDrugs, 2005, 19, 179-187.	2.2	49
53	Therapy Insight: cancer anorexia–cachexia syndrome—when all you can eat is yourself. Nature Clinical Practice Oncology, 2005, 2, 158-165.	4.3	268
54	Gene expression profiling reveals an inflammatory process in the anx/anx mutant mice. Molecular Brain Research, 2005, 139, 372-376.	2.5	25

#	Article	IF	Citations
55	Serum carnitine levels in patients with tumoral cachexia. European Journal of Internal Medicine, 2005, 16, 419-423.	1.0	48
56	Nutrition and Hydration in Children with Cancer. , 2005, , 387-396.		0
57	The Ubiquitin/Proteasome System in Cancer Cachexia. , 2006, , 503-508.		3
58	Non-Gl-Malignancy-Related Malabsorption Leads to Malnutrition and Weight Loss. , 2006, , 509-519.		0
59	Omega-3 Fatty Acids, Cancer Anorexia, and Hypothalamic Gene Expression. , 2006, , 521-536.		0
60	Pharmaco-Nutritional Supports for the Treatment of Cancer Cachexia. , 2006, , 603-617.		0
61	Progestagens and Corticosteroids in the Management Cancer Cachexia. , 2006, , 653-666.		0
62	Anti-TNF-α Antibody and Cancer Cachexia. , 2006, , 673-683.		0
63	A Phase II Study with Antioxidants, both in the Diet and Supplemented, Pharmaco-Nutritional Support, Progestagen and Anti-COX-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia-Cachexia and Oxidative Stress. , 2006, , 685-698.		0
64	Cachexia: Therapeutic Immunomodulation Beyond Cytokine Antagonism. , 2006, , 741-753.		1
65	Anorexia. , 2006, , 139-148.		0
66	Lipid Metabolism in Cachexia. , 2006, , 191-194.		1
67	Leptin and Des-acyl Ghrelin: Their Role in Physiological Body Weight Regulation and in the Pathological State. , 2006, , 247-257.		0
68	Gastrointestinal Diseases. , 2006, , 327-338.		0
69	The Pharmacokinetics and Pharmacodynamics of Drugs in Elderly Cachectic (Cancer) Patients. , 2006, , 377-382.		1
70	Statistically Integrated Metabonomicâ^Proteomic Studies on a Human Prostate Cancer Xenograft Model in Mice. Journal of Proteome Research, 2006, 5, 2642-2655.	1.8	146
71	Skeletal muscle apoptosis is not increased in gastric cancer patients with mild–moderate weight loss. International Journal of Biochemistry and Cell Biology, 2006, 38, 1561-1570.	1.2	18
72	Waste management—Cytokines, growth factors and cachexia. Cytokine and Growth Factor Reviews, 2006, 17, 475-486.	3.2	148

#	Article	IF	CITATIONS
73	Prevention and treatment of cancer cachexia: New insights into an old problem. European Journal of Cancer, 2006, 42, 31-41.	1.3	218
74	Food Insecurity Among Cancer Patients in Kentucky: A Pilot Study. Journal of Oncology Practice, 2006, 2, 274-279.	2.5	44
75	The Effects of Branched-Chain Amino Acids on Canine Neoplastic Cell Proliferation and Death. Journal of Nutrition, 2006, 136, 2007S-2010S.	1.3	13
77	Cachexia: pathophysiology and clinical relevance1,2. American Journal of Clinical Nutrition, 2006, 83, 735-743.	2.2	669
78	Symptom profiles and palliative care in advanced pancreatic cancer—a prospective study. Supportive Care in Cancer, 2006, 14, 1126-1133.	1.0	78
79	Anorexia–Cachexia syndrome in cancer: implications of the ubiquitin–proteasome pathway. Supportive Care in Cancer, 2006, 14, 1173-1183.	1.0	28
80	Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying. Journal of Diabetes and Its Complications, 2006, 20, 56-58.	1.2	16
81	The management of anorexia by patients with advanced cancer: a critical review of the literature. Palliative Medicine, 2006, 20, 623-629.	1.3	31
82	Anorexia in cancer: role of feeding-regulatory peptides. Philosophical Transactions of the Royal Society B: Biological Sciences, 2006, 361, 1281-1289.	1.8	40
83	A Phase II Study with Antioxidants, Both in the Diet and Supplemented, Pharmaconutritional Support, Progestagen, and Anti-Cyclooxygenase-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia/Cachexia and Oxidative Stress. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1030-1034.	1.1	141
84	Symptoms in Children/Young People With Progressive Malignant Disease: United Kingdom Children's Cancer Study Group/Paediatric Oncology Nurses Forum Survey. Pediatrics, 2006, 117, e1179-e1186.	1.0	138
85	Cannabinoids in the Treatment of Symptoms in Cancer and AIDS #93: Megestrol Acetate for Cancer Anorexia/Cachexia #100. Journal of Palliative Medicine, 2006, 9, 802-804.	0.6	7
86	Muscle cachexia is regulated by a p53-PW1/Peg3-dependent pathway. Genes and Development, 2006, 20, 3440-3452.	2.7	104
87	Effects of ghrelin on feeding regulation and interdigestive migrating complex in rats. Scandinavian Journal of Gastroenterology, 2007, 42, 447-453.	0.6	23
88	Pathogenesis and treatment of eating disorders associated with type 1 diabetes mellitus. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 612-613.	2.9	1
89	3Recent Progress Toward Nonpeptide Ligands for the Melanocortin-4 Receptor. Progress in Medicinal Chemistry, 2007, 45, 111-167.	4.1	13
90	Effect on Body Weight and Safety of RCâ€1291, a Novel, Orally Available Ghrelin Mimetic and Growth Hormone Secretagogue: Results of a Phase I, Randomized, Placeboâ€Controlled, Multipleâ€Dose Study in Healthy Volunteers. Oncologist, 2007, 12, 594-600.	1.9	115
91	Nutritional Support in Cancer. Current Nutrition and Food Science, 2007, 3, 242-248.	0.3	0

#	Article	IF	CITATIONS
92	Initiation and Discontinuation of Complementary Therapy Among Cancer Patients. Journal of Clinical Oncology, 2007, 25, 5267-5274.	0.8	19
93	Endocannabinoid system in cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10, 443-448.	1.3	19
94	Pro-inflammatory cytokines and oxidative stress/antioxidant parameters characterize the bio-humoral profile of early cachexia in lung cancer patients. Oncology Reports, 0, , .	1.2	16
95	Interleukin 6 Is Associated with Cachexia in Patients with Prostate Cancer. Urology, 2007, 69, 113-117.	0.5	101
96	Cannabinoid-induced hyperphagia: Correlation with inhibition of proopiomelanocortin neurons?. Physiology and Behavior, 2007, 92, 507-519.	1.0	33
97	Clinical Significance of Ghrelin Concentration of Plasma and Tumor Tissue in Patients with Gastric Cancer. Journal of Surgical Research, 2007, 143, 344-349.	0.8	38
98	Role of Corticosteroids in Palliative Care. Journal of Pain and Palliative Care Pharmacotherapy, 2007, 21, 69-76.	0.5	77
99	Ghrelin, the peripheral hunger hormone. Annals of Medicine, 2007, 39, 116-136.	1.5	127
100	Common Gastrointestinal Symptoms in Pediatric Palliative Care: Nausea, Vomiting, Constipation, Anorexia, Cachexia. Pediatric Clinics of North America, 2007, 54, 673-689.	0.9	28
101	An Innovative Treatment Approach for Cancer-Related Anorexia/Cachexia and Oxidative Stress: Background and Design of an Ongoing, Phase III, Randomized Clinical Trial. Supportive Cancer Therapy, 2007, 4, 163-167.	0.3	5
102	Nutrition Assessment and Hormonal Influences on Body Composition in Children with Chronic Kidney Disease. Advances in Chronic Kidney Disease, 2007, 14, 215-223.	0.6	19
103	Cancer cachexia syndrome in head and neck cancer patients: Part I. Diagnosis, impact on quality of life and survival, and treatment. Head and Neck, 2007, 29, 401-411.	0.9	116
104	Cancer cachexia syndrome in head and neck cancer patients: Part II. Pathophysiology. Head and Neck, 2007, 29, 497-507.	0.9	41
105	Impact of weight loss on circulating IL-1, IL-6, IL-8, TNF-α, VEGF-A, VEGF–C and midkine in gastroesophageal cancer patients. Clinical Biochemistry, 2007, 40, 1353-1360.	0.8	63
106	Assessing Energy Expenditure in Cancer Patients: A Pilot Validation of a New Wearable Device. Journal of Parenteral and Enteral Nutrition, 2007, 31, 502-507.	1.3	71
108	Metabolomic analysis of cancer cachexia reveals distinct lipid and glucose alterations. Metabolomics, 2008, 4, 216-225.	1.4	45
109	Anaerobic exercise reduces tumor growth, cancer cachexia and increases macrophage and lymphocyte response in Walker 256 tumor-bearing rats. European Journal of Applied Physiology, 2008, 104, 957-964.	1.2	56
110	Effect of endurance training upon lipid metabolism in the liver of cachectic tumourâ€bearing rats. Cell Biochemistry and Function, 2008, 26, 701-708.	1.4	45

#	Article	IF	CITATIONS
111	Lipolysis—Not inflammation, cell death, or lipogenesis—Is involved in adipose tissue loss in cancer cachexia. Cancer, 2008, 113, 1695-1704.	2.0	140
112	Impact of Body Mass Index on Perioperative Outcomes in Patients Undergoing Major Intra-abdominal Cancer Surgery. Annals of Surgical Oncology, 2008, 15, 2164-2172.	0.7	303
113	Serum levels of tumour necrosis factor-α and interleukin-6 and their correlation with body mass index, weight loss, appetite and survival rate - preliminary data of Viennese outpatients with metastatic cancer during palliative chemotherapy. European Journal of Cancer Care, 2008, 17, 454-462.	0.7	15
114	Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia. BMC Cancer, 2008, 8, 85.	1.1	7
115	Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition, 2008, 24, 305-313.	1.1	90
116	Cancer cachexia: Measured and predicted resting energy expenditures for nutritional needs evaluation. Nutrition, 2008, 24, 443-450.	1.1	40
117	Chrelin and ghrelin receptor inhibitors: agents in the treatment of obesity. Expert Opinion on Therapeutic Targets, 2008, 12, 1177-1189.	1.5	34
118	Déconditionnement et réhabilitation du patient cancéreux. Kinesitherapie, 2008, 8, 32-37.	0.0	2
119	The Marriage of Conventional Cancer Treatments and Alternative Cancer Therapies. Nursing Clinics of North America, 2008, 43, 221-241.	0.7	0
120	The Cytokine Basis of Cachexia and its Treatment: Are They Ready for Prime Time?. Journal of the American Medical Directors Association, 2008, 9, 219-236.	1.2	57
121	The Biological Mechanisms of Cancer-Related Skeletal Muscle Wasting: The Role of Progressive Resistance Exercise. Biological Research for Nursing, 2008, 10, 7-20.	1.0	80
122	Acute-phase response proteins are related to cachexia and accelerated angiogenesis in gastroesophageal cancers. Clinical Chemistry and Laboratory Medicine, 2008, 46, 359-64.	1.4	76
123	Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. British Journal of Cancer, 2008, 98, 300-308.	2.9	146
125	Hypothalamus transcriptome profile suggests an anorexia-cachexia syndrome in the anx/anx mouse model. Physiological Genomics, 2008, 35, 341-350.	1.0	22
126	The role of ghrelin and ghrelin analogues in wasting disease. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 443-451.	1.3	37
127	Serial Plasma Concentrations of PYY and Ghrelin During Chemotherapy in Children With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2008, 30, 733-737.	0.3	15
128	Selective androgen receptor modulators in preclinical and clinical development. Nuclear Receptor Signaling, 2008, 6, nrs.06010.	1.0	129
129	Cannabinoids as novel anti-inflammatory drugs. Future Medicinal Chemistry, 2009, 1, 1333-1349.	1.1	385

#	ARTICLE	IF	CITATIONS
130	Sex Differences in the Cannabinoid Modulation of Appetite, Body Temperature and Neurotransmission at POMC Synapses. Neuroendocrinology, 2009, 89, 424-440.	1.2	49
131	A Framework for Assessment in Oncology Rehabilitation. Physical Therapy, 2009, 89, 286-306.	1.1	89
132	Validation of a Simplified Anorexia Questionnaire. Journal of Pain and Symptom Management, 2009, 38, 691-697.	0.6	14
133	The experience of cancer cachexia: A qualitative study of advanced cancer patients and their family members. International Journal of Nursing Studies, 2009, 46, 606-616.	2.5	107
134	Nutrition impact symptoms: Key determinants of reduced dietary intake, weight loss, and reduced functional capacity of patients with head and neck cancer before treatment. Head and Neck, 2010, 32, 290-300.	0.9	136
135	Components of the anorexia–cachexia syndrome: gastrointestinal symptom correlates of cancer anorexia. Supportive Care in Cancer, 2009, 17, 1531-1541.	1.0	35
136	New perspective on the nutritional approach to cancer-related anorexia/cachexia: preliminary results of a randomised phase III clinical trial with five different arms of treatment. Mediterranean Journal of Nutrition and Metabolism, 2009, 2, 29-36.	0.2	1
137	Elective gastrostomy, nutritional status and quality of life in advanced head and neck cancer patients receiving chemoradiotherapy. ANZ Journal of Surgery, 2009, 79, 713-718.	0.3	52
138	Cachexia in pancreatic cancer – Mechanisms and potential intervention. European E-journal of Clinical Nutrition and Metabolism, 2009, 4, e337-e343.	0.4	1
139	Introduction. Seminars in Oncology Nursing, 2009, 25, 1-2.	0.7	3
139 140	Introduction. Seminars in Oncology Nursing, 2009, 25, 1-2. Anorexia in chronic obstructive pulmonary disease — Association to cachexia and hormonal derangement. International Journal of Cardiology, 2009, 132, 434.	0.7	3 2
	Anorexia in chronic obstructive pulmonary disease $\hat{a} \in \mathbb{C}$ Association to cachexia and hormonal		
140	Anorexia in chronic obstructive pulmonary disease — Association to cachexia and hormonal derangement. International Journal of Cardiology, 2009, 132, 434.	0.8	2
140 141	 Anorexia in chronic obstructive pulmonary disease — Association to cachexia and hormonal derangement. International Journal of Cardiology, 2009, 132, 434. Powerful signals for weak muscles. Ageing Research Reviews, 2009, 8, 251-267. Selective Serotonin Reuptake Inhibitors Modify Physiological Gastrointestinal Motor Activities via 	0.8 5.0	2 94
140 141 142	 Anorexia in chronic obstructive pulmonary disease — Association to cachexia and hormonal derangement. International Journal of Cardiology, 2009, 132, 434. Powerful signals for weak muscles. Ageing Research Reviews, 2009, 8, 251-267. Selective Serotonin Reuptake Inhibitors Modify Physiological Gastrointestinal Motor Activities via 5-HT2c Receptor and Acyl Ghrelin. Biological Psychiatry, 2009, 65, 748-759. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: Evaluation of clinical and dosimetric parameters. Lung Cancer, 	0.8 5.0 0.7	2 94 107
140 141 142 143	 Anorexia in chronic obstructive pulmonary disease — Association to cachexia and hormonal derangement. International Journal of Cardiology, 2009, 132, 434. Powerful signals for weak muscles. Ageing Research Reviews, 2009, 8, 251-267. Selective Serotonin Reuptake Inhibitors Modify Physiological Gastrointestinal Motor Activities via 5-HT2c Receptor and Acyl Ghrelin. Biological Psychiatry, 2009, 65, 748-759. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: Evaluation of clinical and dosimetric parameters. Lung Cancer, 2009, 63, 393-399. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer 	0.8 5.0 0.7 0.9	2 94 107 56
140 141 142 143 144	 Anorexia in chronic obstructive pulmonary disease — Association to cachexia and hormonal derangement. International Journal of Cardiology, 2009, 132, 434. Powerful signals for weak muscles. Ageing Research Reviews, 2009, 8, 251-267. Selective Serotonin Reuptake Inhibitors Modify Physiological Gastrointestinal Motor Activities via 5-HT2c Receptor and Acyl Ghrelin. Biological Psychiatry, 2009, 65, 748-759. Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: Evaluation of clinical and dosimetric parameters. Lung Cancer, 2009, 63, 393-399. Increased serum levels of ghrelin at diagnosis mediate body weight loss in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 2009, 66, 393-398. Living with Head and Neck Cancer and Coping with Dying when Treatments Fail. Otolaryngologic 	0.8 5.0 0.7 0.9	2 94 107 56 35

		LEPORT	
#		IF	CITATIONS
148	Nutrition in the last days of life. Current Opinion in Supportive and Palliative Care, 2009, 3, 195-202.	0.5	3
149	Attenuation of proteolysis and muscle wasting by curcumin c3 complex in MAC16 colon tumour-bearing mice. British Journal of Nutrition, 2009, 102, 967-975.	1.2	49
150	Improving nutritional management within high-risk groups. British Journal of General Practice, 2009, 59, 595-596.	0.7	2
151	Pathogenesis of muscle wasting in cancer cachexia: targeted anabolic and anticatabolic therapies. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 410-416.	1.3	43
153	Inflammation and cachexia in chronic kidney disease. Pediatric Nephrology, 2010, 25, 711-724.	0.9	134
154	Body weight and fat-free mass changes in a cohort of patients receiving chemotherapy. Supportive Care in Cancer, 2010, 18, 617-625.	1.0	28
155	Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. Mediterranean Journal of Nutrition and Metabolism, 2010, 3, 165-172.	0.2	5
157	Parathyroid hormone-related protein has an anorexigenic activity via activation of hypothalamic urocortins 2 and 3. Psychoneuroendocrinology, 2010, 35, 1178-1186.	1.3	21
158	Appetite and gastrointestinal motility: Role of ghrelin-family peptides. Clinical Nutrition, 2010, 29, 227-234.	2.3	28
159	Weight loss in head and neck cancer patients little noticed in general practice. Journal of Primary Health Care, 2010, 2, 16.	0.2	36
160	Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia. Oncologist, 2010, 15, 200-211.	1.9	185
161	Interleukin-10 Gene Polymorphisms Influence Susceptibility to Cachexia in Patients with Low-Third Gastric Cancer in a Chinese Population. Molecular Diagnosis and Therapy, 2010, 14, 95-100.	1.6	9
162	Association of Interleukin-8 Gene Polymorphism With Cachexia From Patients With Gastric Cancer. Journal of Interferon and Cytokine Research, 2010, 30, 9-14.	0.5	29
164	Current and potential roles of ghrelin in clinical practice. Journal of Endocrinological Investigation, 2010, 33, 823-838.	1.8	27
165	Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology, 2010, 215, 598-605.	0.8	195
166	The Cachexia Assessment Scale: Development and Psychometric Properties. Oncology Nursing Forum, 2010, 37, 635-640.	0.5	5
167	Osteopontin as a marker of weight loss in lung cancer. Scandinavian Journal of Clinical and Laboratory Investigation, 2011, 71, 690-694.	0.6	12
168	Potentiation of ghrelin signaling attenuates cancer anorexia–cachexia and prolongs survival. Translational Psychiatry, 2011, 1, e23-e23.	2.4	128

#	Article	IF	CITATIONS
169	Assessment and Management of Gastrointestinal Symptoms in Advanced Illness. Primary Care - Clinics in Office Practice, 2011, 38, 225-246.	0.7	9
170	Identification of serum proteins involved in pancreatic cancer cachexia. Life Sciences, 2011, 88, 218-225.	2.0	43
171	Metformin reduces the stimulatory effect of obesity on in vivo Walker-256 tumor development and increases the area of tumor necrosis. Life Sciences, 2011, 88, 846-852.	2.0	19
172	Cachexia, Malnutrition, the Refeeding Syndrome, and Lessons from Goldilocks. Surgical Clinics of North America, 2011, 91, 653-673.	0.5	25
173	Clinical and nutritional status of surgical patients with and without malignant diseases: cross-sectional study. Arquivos De Gastroenterologia, 2011, 48, 58-61.	0.3	13
174	Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncology Reports, 2011, 27, 318-24.	1.2	35
175	Poor tolerability of thalidomide in end-stage oesophageal cancer. European Journal of Cancer Care, 2011, 20, 593-600.	0.7	26
176	Hypothalamic inflammation: a doubleâ€edged sword to nutritional diseases. Annals of the New York Academy of Sciences, 2011, 1243, E1-39.	1.8	131
177	Characterization of Chemosensory Alterations in Advanced Cancer Reveals Specific Chemosensory Phenotypes Impacting Dietary Intake and Quality of Life. Journal of Pain and Symptom Management, 2011, 41, 673-683.	0.6	63
178	Targeting the Ubiquitin E3 Ligase MuRF1 to Inhibit Muscle Atrophy. Cell Biochemistry and Biophysics, 2011, 60, 113-118.	0.9	47
179	Metastin is not involved in metastatic potential of non-small cell lung cancer. Medical Oncology, 2011, 28, 559-564.	1.2	11
180	Comparison of PG-SGA, SGA and body-composition measurement in detecting malnutrition among newly diagnosed lung cancer patients in stage IIIB/IV and benign conditions. Medical Oncology, 2011, 28, 689-696.	1.2	43
181	Pathophysiology and Treatment Options for Cardiac Anorexia. Current Heart Failure Reports, 2011, 8, 147-153.	1.3	13
182	A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study. BMC Cancer, 2011, 11, 493.	1.1	38
183	CALPAIN activity is increased in skeletal muscle from gastric cancer patients with no or minimal weight loss. Muscle and Nerve, 2011, 43, 410-414.	1.0	43
184	Survival of patients with palliative head and neck cancer. Head and Neck, 2011, 33, 1021-1026.	0.9	27
185	Pretreatment nutritional status and locoregional failure of patients with head and neck cancer undergoing definitive concurrent chemoradiation therapy. Head and Neck, 2011, 33, 1561-1568.	0.9	36
186	Nutritional Interventions for Cancer-Induced Cachexia. Current Problems in Cancer, 2011, 35, 58-90.	1.0	99

#	Article	IF	CITATIONS
187	Nutrition in the care of patients with cancer cachexia. British Journal of Community Nursing, 2011, 16, 314-323.	0.2	1
188	Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Annals of Oncology, 2011, 22, 835-841.	0.6	74
189	Understanding cancer-induced cachexia. Current Opinion in Supportive and Palliative Care, 2011, 5, 327-333.	0.5	11
190	Metabolic Signatures Imaged in Cancer-Induced Cachexia. Cancer Research, 2011, 71, 6948-6956.	0.4	26
191	Food meanings in HIV and AIDS caregiving trajectories: Ritual, optimism and anguish among caregivers in Lesotho. Psychology, Health and Medicine, 2011, 16, 190-202.	1.3	11
192	The Bill Henderson Protocol. Journal of Evidence-Based Complementary & Alternative Medicine, 2011, 16, 226-232.	1.5	2
193	Branch chain amino acid and melanogenesis. Immunopharmacology and Immunotoxicology, 2012, 34, 539-539.	1.1	1
194	Management of Anorexia-Cachexia in Late-Stage Lung Cancer Patients. Journal of Hospice and Palliative Nursing, 2012, 14, 397-402.	0.5	28
195	Improved Outcomes in the Malnourished Patient: We're Not There Yet. Journal of the National Cancer Institute, 2012, 104, 342-343.	3.0	8
196	Cancer Cachexia Care. Cancer Nursing, 2012, 35, E30-E38.	0.7	25
197	Glutamine as a supplemental treatment in pediatric and adult oncology patients. Expert Opinion on Investigational Drugs, 2012, 21, 1861-1871.	1.9	7
198	Morphological and immunological changes in the skin of autopsied women with AIDS. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 461, 449-455.	1.4	3
199	Estradiol signaling in the regulation of reproduction and energy balance. Frontiers in Neuroendocrinology, 2012, 33, 342-363.	2.5	71
200	The role of insulin resistance in the development of muscle wasting during cancer cachexia. Journal of Cachexia, Sarcopenia and Muscle, 2012, 3, 5-11.	2.9	140
201	Nutrition in patients on peritoneal dialysis. Nature Reviews Nephrology, 2012, 8, 163-175.	4.1	57
202	Adipose tissue inflammation and cancer cachexia: Possible role of nuclear transcription factors. Cytokine, 2012, 57, 9-16.	1.4	79
203	Lost in translation: regulation of skeletal muscle protein synthesis. Current Opinion in Pharmacology, 2012, 12, 377-382.	1.7	37
204	Thalidomide for managing cancer cachexia. The Cochrane Library, 2021, 2021, CD008664.	1.5	41

#	Article	IF	CITATIONS
205	Prognostic Role of Host Cyclooxygenase and Cytokine Genotypes in a Caucasian Cohort of Patients with Gastric Adenocarcinoma. PLoS ONE, 2012, 7, e46179.	1.1	9
208	Adipokines and Systemic Inflammation in Weight-Losing Lung Cancer Patients. Lung, 2012, 190, 327-332.	1.4	42
209	l-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Amino Acids, 2012, 42, 1783-1792.	1.2	25
210	Randomized phase III clinical trial of a combined treatment with carnitineÂ+Âcelecoxib±Âmegestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clinical Nutrition, 2012, 31, 176-182.	2.3	108
211	Phytocannabinoids as novel therapeutic agents in CNS disorders. , 2012, 133, 79-97.		258
212	A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: Evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecologic Oncology, 2012, 124, 417-425.	0.6	121
213	Changes in Myostatin Signaling in Non-Weight-Losing Cancer Patients. Annals of Surgical Oncology, 2012, 19, 1350-1356.	0.7	68
214	Characterization of the Yoshida sarcoma: a model of cancer cachexia. Supportive Care in Cancer, 2013, 21, 2687-2694.	1.0	7
215	Cancer cachexia—pathophysiology and management. Journal of Gastroenterology, 2013, 48, 574-594.	2.3	196
216	Megestrol acetate for treatment of anorexia-cachexia syndrome. The Cochrane Library, 2019, 2019, CD004310.	1.5	147
217	Body mass index and outcomes following gastrointestinal cancer surgery in Japan. British Journal of Surgery, 2013, 100, 1335-1343.	0.1	89
218	Anorexia and Hypothalamic Degeneration. Vitamins and Hormones, 2013, 92, 27-60.	0.7	11
219	Brain activity correlated with food preferences: A functional study comparing advanced non-small cell lung cancer patients with and without anorexia. Nutrition, 2013, 29, 1013-1019.	1.1	15
220	Prognostic relationship of metabolic profile obtained of melanoma B16F10. Biomedicine and Pharmacotherapy, 2013, 67, 146-156.	2.5	16
221	Stan psychoemocjonalny rodziców i dzieci chorujÄ…cych na nowotwory ukÅ,adu krwiotwórczego w trakcie steroidoterapii. Pediatria Polska, 2013, 88, 170-176.	0.1	0
222	Impact of Weight Change During the Course of Concurrent Chemoradiation Therapy on Outcomes in Stage IIIB Non-Small Cell Lung Cancer Patients: Retrospective Analysis of 425 Patients. International Journal of Radiation Oncology Biology Physics, 2013, 87, 697-704.	0.4	54
224	Supportive Care for the Cancer Patient. , 2013, , 245-279.		0
225	Gene Expression Changes in Spleens and Livers of Tumour-Bearing Mice Suggest Delayed Inflammation and Attenuated Cachexia in Response to Oil Palm Phenolics. Journal of Nutrigenetics and Nutrigenomics, 2013, 6, 305-326.	1.8	9

#	Article	IF	CITATIONS
226	Cancer Cachexia Pathophysiology and Translational Aspect of Herbal Medicine. Japanese Journal of Clinical Oncology, 2013, 43, 695-705.	0.6	31
227	Erlotinib Plus Parenteral Nutrition. American Journal of Hospice and Palliative Medicine, 2013, 30, 210-213.	0.8	1
228	Is There a Best Nutrition Approach for Cancer Survivors?. Nutrition Today, 2013, 48, 210-218.	0.6	1
229	Home Artificial Nutrition in Advanced Cancer Patients. Tumori, 2013, 99, 218-224.	0.6	16
230	Can Behenic Acid (C22:0) Levels be a Prognostic Factor in Glial Tumors?. Canadian Journal of Neurological Sciences, 2013, 40, 854-856.	0.3	6
231	Measurement of mid-arm muscle circumference and prognosis in stage IV non-small cell lung cancer patients. Oncology Letters, 2013, 5, 1063-1067.	0.8	18
232	Nutrition in oncologic patients during antiblastic treatment. Frontiers in Bioscience - Landmark, 2013, 18, 120.	3.0	2
234	Clues to ovarian tumors: new concepts of symptoms, signs, syndromes, and paraneoplastic syndromes. , 0, , 325-348.		0
235	Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer & Metabolism, 2014, 2, 18.	2.4	182
236	Rikkunshito, a ghrelin potentiator, ameliorates anorexiaââ,¬â€œcachexia syndrome. Frontiers in Pharmacology, 2014, 5, 271.	1.6	55
237	Functional capacity and fear of falling in cancer patients undergoing chemotherapy. Gait and Posture, 2014, 39, 865-869.	0.6	37
238	MicroRNA profiling links miR-378 to enhanced adipocyte lipolysis in human cancer cachexia. American Journal of Physiology - Endocrinology and Metabolism, 2014, 306, E267-E274.	1.8	57
239	Nutrition impact symptoms in a population cohort of head and neck cancer patients: Multivariate regression analysis of symptoms on oral intake, weight loss and survival. Oral Oncology, 2014, 50, 877-883.	0.8	97
240	Obesity was associated with a decreased postoperative recurrence of rectal cancer in a Japanese population. Surgery Today, 2014, 44, 2324-2331.	0.7	16
241	Anorexia–cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach. Advances in Medical Sciences, 2014, 59, 1-6.	0.9	35
242	Introduction: What to Eat when you Can't Eat. Global Advances in Health and Medicine, 2014, 3, 56-72.	0.7	3
243	Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment. Journal of Cachexia, Sarcopenia and Muscle, 2015, 6, 303-311.	2.9	77
244	Endostatin improves cancer-associated systemic syndrome in a lung cancer model. Oncology Letters, 2015, 9, 2023-2030.	0.8	1

#	Article	IF	CITATIONS
245	Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients with Cancer. Cancer Control, 2015, 22, 403-411.	0.7	4
246	The Impact of Body Mass Index on the Surgical Outcomes of Patients With Gastric Cancer. Medicine (United States), 2015, 94, e1769.	0.4	90
247	ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation. Annals of Oncology, 2015, 26, vii-viii.	0.6	20
248	Cachexia & debility diagnoses in hospitalized children and adolescents with complex chronic conditions: evidence from the Kids' Inpatient Database. Drugs in Context, 2015, 4, 1-14.	1.0	4
249	Cancer Pain $\hat{a} \in \hat{~}$ The Role of an Integrated, Comprehensive Rehabilitation Program in Its Management. , 0, , .		4
250	Cancer cachexia, mechanism and treatment. World Journal of Gastrointestinal Oncology, 2015, 7, 17.	0.8	323
251	Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: An in vitro and in vivo study. Oncology Reports, 2015, 33, 2261-2268.	1.2	84
252	Cancer Cachexia Syndrome: Pathogenesis, Diagnosis, and New Therapeutic Options. Nutrition and Cancer, 2015, 67, 12-26.	0.9	53
253	Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials. Cancer and Metastasis Reviews, 2015, 34, 359-380.	2.7	118
254	Glucocorticoids and Cancer. Advances in Experimental Medicine and Biology, 2015, 872, 315-333.	0.8	154
255	Male Reproductive Cancers and Infertility: A Mutual Relationship. International Journal of Molecular Sciences, 2015, 16, 7230-7260.	1.8	46
256	Histone Deacetylase 6 Is a FoxO Transcription Factor-dependent Effector in Skeletal Muscle Atrophy. Journal of Biological Chemistry, 2015, 290, 4215-4224.	1.6	34
257	Metformin reduces the Walker-256 tumor development in obese-MSG rats via AMPK and FOXO3a. Life Sciences, 2015, 121, 78-87.	2.0	15
258	Comparison of Survival Rates, Tumor Stages, and Localization in between Obese and Nonobese Patients with Gastric Cancer. Gastroenterology Research and Practice, 2016, 2016, 1-5.	0.7	4
259	Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. European Respiratory Review, 2016, 25, 472-486.	3.0	225
260	Sip-jeon-dea-bo-tang, a traditional herbal medicine, ameliorates cisplatin-induced anorexia via the activation of JAK1/STAT3-mediated leptin and IL-6 production in the fat tissue of mice. Molecular Medicine Reports, 2016, 13, 2967-2972.	1.1	14
261	Are Four Simple Questions Able to Predict Weight Loss in Outpatients With Metastatic Cancer? A Prospective Cohort Study Assessing the Simplified Nutritional Appetite Questionnaire. Nutrition and Cancer, 2016, 68, 743-749.	0.9	7
262	Sosiho-tang ameliorates cachexia-related symptoms in mice bearing colon 26 adenocarcinoma by reducing systemic inflammation and muscle loss. Oncology Reports, 2016, 35, 1841-1850.	1.2	17

#	Article	IF	CITATIONS
263	Cancer cachexia—when proteasomal inhibition is not enough. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 239-245.	2.9	14
264	Citrus unshiu peel extract alleviates cancer-induced weight loss in mice bearing CT-26 adenocarcinoma. Scientific Reports, 2016, 6, 24214.	1.6	31
265	Assessment of physical function in geriatric oncology based on International Classification of Functioning, Disability and Health (ICF) framework. Current Geriatrics Reports, 2016, 5, 200-212.	1.1	0
266	Investigation of the expression of irisin and some cachectic factors in mice with experimentally induced gastric cancer. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 785-790.	0.2	27
267	European medicinal and edible plants associated with subacute and chronic toxicity part II: Plants with hepato-, neuro-, nephro- and immunotoxic effects. Food and Chemical Toxicology, 2016, 92, 38-49.	1.8	27
268	Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 225-232.	2.9	37
269	Effect of chemoradiotherapy on nutrition status of patients with nasopharyngeal cancer. Nutrition and Cancer, 2016, 68, 63-69.	0.9	28
270	White adipose tissue cells and the progression of cachexia: inflammatory pathways. Journal of Cachexia, Sarcopenia and Muscle, 2016, 7, 193-203.	2.9	44
271	Loss of muscle mass: Current developments in cachexia and sarcopenia focused on biomarkers and treatment. International Journal of Cardiology, 2016, 202, 766-772.	0.8	18
272	Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis. Journal of Cancer Survivorship, 2017, 11, 339-349.	1.5	96
273	Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis. Supportive Care in Cancer, 2017, 25, 1651-1659.	1.0	41
274	Preoperative and postoperative nutrition in hepatobiliary surgery. , 2017, , 445-458.e5.		2
275	L-leucine dietary supplementation modulates muscle protein degradation and increases pro-inflammatory cytokines in tumour-bearing rats. Cytokine, 2017, 96, 253-260.	1.4	33
276	JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia. Endocrine, 2017, 58, 106-114.	1.1	15
277	The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. Future Oncology, 2017, 13, 1767-1783.	1.1	10
278	Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice. European Journal of Pharmacology, 2017, 811, 30-37.	1.7	17
279	Cancer Immunotherapy: Friend or Foe of Mental Health?. , 2017, , 789-823.		0
280	Energy imbalance and cancer: Cause or consequence?. IUBMB Life, 2017, 69, 776-784.	1.5	6

#	Article	IF	CITATIONS
281	Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma. Nutrition, 2017, 36, 67-71.	1.1	20
282	Cancer-induced cardiac cachexia: Pathogenesis and impact of physical activity. Oncology Reports, 2017, 37, 2543-2552.	1.2	55
283	IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm. Translational Cancer Research, 2017, 6, S280-S285.	0.4	33
284	Centella asiatica modulates cancer cachexia associated inflammatory cytokines and cell death in leukaemic THP-1 cells and peripheral blood mononuclear cells (PBMC's). BMC Complementary and Alternative Medicine, 2017, 17, 377.	3.7	13
285	Withania somnifera modulates cancer cachexia associated inflammatory cytokines and cell death in leukaemic THP-1 cells and peripheral blood mononuclear cells (PBMC's). BMC Complementary and Alternative Medicine, 2018, 18, 126.	3.7	21
286	The Role of Palliative Care in Lung Cancer. , 2018, , 608-619.e8.		0
287	Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a. European Journal of Pharmacology, 2018, 818, 148-157.	1.7	14
288	Motor Neuron-Skeletal Muscle Co Culture Model: A Potential Novel in Vitro and Computaional Platform to Investigate Cancer Cachexia. , 2018, , .		0
289	Herbal Medicine Ninjin'yoeito in the Treatment of Sarcopenia and Frailty. Frontiers in Nutrition, 2018, 5, 126.	1.6	39
290	Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. Journal of Ethnopharmacology, 2018, 227, 300-315.	2.0	378
291	The role of cyclooxygenase inhibitors in lipopolysaccharide-induced hypophagia in chicken. Czech Journal of Animal Science, 2015, 60, 342-350.	0.5	6
292	Endocannabinoids in Body Weight Control. Pharmaceuticals, 2018, 11, 55.	1.7	38
293	Cachexia/Anorexia and Feeding Difficulties. , 2018, , 1-20.		0
294	Tracheostomies and PEGs. Surgical Clinics of North America, 2019, 99, 955-965.	0.5	7
295	Cancer Anorexia-Cachexia Syndrome. , 2019, , 981-985.		1
296	Ten years of Croatian national guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome – Evaluation of awareness and implementation among Croatian oncologists. Clinical Nutrition ESPEN, 2019, 33, 202-206.	0.5	0
297	Cachexia/Anorexia and Feeding Difficulties. , 2019, , 275-293.		0
298	Impact of habitual marijuana and tobacco smoke on severity of chronic rhinosinusitis. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2019, 40, 583-588.	0.6	5

#	Article	IF	CITATIONS
299	Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. Journal of Cachexia, Sarcopenia and Muscle, 2019, 10, 22-34.	2.9	113
300	Symptoms of and Palliative Treatment for Unresectable Skin Cancer. Current Treatment Options in Oncology, 2019, 20, 34.	1.3	9
301	Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice. Journal of Cellular Physiology, 2019, 234, 18041-18052.	2.0	14
302	Oncologic evaluation of obesity as a factor in patients with rectal cancer undergoing laparoscopic surgery: a propensity-matched analysis using body mass index. Annals of Surgical Treatment and Research, 2019, 96, 86.	0.4	6
303	Nutrition and Cancercapsaicin Treatment Reduces Tumor Growth, Tumor Cell Proliferation Ex Vivo and Partially Reverses Cancer Cachexia in Walker 256 Tumor-Bearing Rats. Nutrition and Cancer, 2019, 71, 111-117.	0.9	5
304	Sarcopenia – Endocrinological and Neurological Aspects. Experimental and Clinical Endocrinology and Diabetes, 2019, 6, 8-22.	0.6	23
305	Higher serum levels of fibroblast growth factor 21 in old patients with cachexia. Nutrition, 2019, 63-64, 81-86.	1.1	21
306	Evaluation of weight loss in canine cancer bearing patients undergoing radiation therapy. Veterinary and Comparative Oncology, 2020, 18, 184-190.	0.8	3
307	Exercise as an anti-inflammatory therapy for cancer cachexia: a focus on interleukin-6 regulation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2020, 318,	0.9	48
	R296-R310.		
308	Supportive Care for the Cancer Patient. , 2020, , 286-329.		1
308 309		1.7	1 17
	Supportive Care for the Cancer Patient. , 2020, , 286-329. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer	1.7	
309	Supportive Care for the Cancer Patient. , 2020, , 286-329. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 1880. Impact of Body Mass Index on Outcomes After Breast Cancer Surgery: Nationwide Inpatient Database		17
309 310	Supportive Care for the Cancer Patient., 2020, , 286-329. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 1880. Impact of Body Mass Index on Outcomes After Breast Cancer Surgery: Nationwide Inpatient Database Study in Japan. Clinical Breast Cancer, 2020, 20, e663-e674. Associations between Pregnane X Receptor and Breast Cancer Growth and Progression. Cells, 2020, 9,	1.1	17 10
309 310 311	Supportive Care for the Cancer Patient. , 2020, , 286-329. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 1880. Impact of Body Mass Index on Outcomes After Breast Cancer Surgery: Nationwide Inpatient Database Study in Japan. Clinical Breast Cancer, 2020, 20, e663-e674. Associations between Pregnane X Receptor and Breast Cancer Growth and Progression. Cells, 2020, 9, 2295.	1.1	17 10 8
309 310 311 312	Supportive Care for the Cancer Patient., 2020, , 286-329. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 1880. Impact of Body Mass Index on Outcomes After Breast Cancer Surgery: Nationwide Inpatient Database Study in Japan. Clinical Breast Cancer, 2020, 20, e663-e674. Associations between Pregnane X Receptor and Breast Cancer Growth and Progression. Cells, 2020, 9, 2295. Adipose Tissue Remodeling during Cancer Cachexia., 2020, . Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. Journal of	1.1	17 10 8 1
309 310 311 312 313	Supportive Care for the Cancer Patient., 2020, , 286-329. Leucine-Rich Diet Modulates the Metabolomic and Proteomic Profile of Skeletal Muscle during Cancer Cachexia. Cancers, 2020, 12, 1880. Impact of Body Mass Index on Outcomes After Breast Cancer Surgery: Nationwide Inpatient Database Study in Japan. Clinical Breast Cancer, 2020, 20, e663-e674. Associations between Pregnane X Receptor and Breast Cancer Growth and Progression. Cells, 2020, 9, 2295. Adipose Tissue Remodeling during Cancer Cachexia., 2020, ,. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. Journal of Cachexia, Sarcopenia and Muscle, 2020, 11, 619-635. Incidence of cachexia in patients with advanced gastrointestinal cancer at the beginning of	1.1 1.8 2.9	17 10 8 1 172

#	Article	IF	CITATIONS
317	The Emerging Role of MicroRNAs and Other Non-Coding RNAs in Cancer Cachexia. Cancers, 2020, 12, 1004.	1.7	30
318	Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison. Pharmacological Reports, 2021, 73, 17-30.	1.5	29
319	Approach to Patients with Unintentional Weight Loss. Medical Clinics of North America, 2021, 105, 175-186.	1.1	15
320	Tumour-regulated anorexia preceding cachexia. Nature Cell Biology, 2021, 23, 111-113.	4.6	4
321	Exercise Training as Therapeutic Approach in Cancer Cachexia: A Review of Potential Anti-inflammatory Effect on Muscle Wasting. Frontiers in Physiology, 2020, 11, 570170.	1.3	18
322	Serum insulinâ€like growth factor binding protein 2 levels as biomarker for pancreatic ductal adenocarcinomaâ€associated malnutrition and muscle wasting. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 704-716.	2.9	15
323	The mechanism by which noncoding RNAs regulate muscle wasting in cancer cachexia. Precision Clinical Medicine, 2021, 4, 136-147.	1.3	5
324	Clinical malnutrition predictive model among gynecologic cancer patients prior to elective operation: A cross-sectional study. Clinical Nutrition, 2021, 40, 4373-4379.	2.3	9
325	An integrative transcriptome study reveals Ddit4/Redd1 as a key regulator of cancer cachexia in rodent models. Cell Death and Disease, 2021, 12, 652.	2.7	16
326	Enteral Nutrition Combined with Improved-Sijunzi Decoction Shows Positive Effect in Precachexia Cancer Patients: A Retrospective Analysis. Evidence-based Complementary and Alternative Medicine, 2021, 2021, 1-8.	0.5	3
327	Lipopolysaccharide inhibits hypothalamic Agouti-related protein gene expression via activating mechanistic target of rapamycin signaling in chicks. General and Comparative Endocrinology, 2021, 313, 113876.	0.8	1
330	Multiple Effects Cost-Effectiveness Analysis in Cost-Disutility Space. , 2017, , 229-251.		1
331	Gastrointestinal Symptoms. , 2011, , 311-334.		5
332	Tratamiento de los sÃntomas digestivos. Atencion Primaria, 2006, 38, 47-56.	0.6	2
333	Anorexia. , 2005, , 17-30.		1
334	TGF-β Blockade Reduces Mortality and Metabolic Changes in a Validated Murine Model of Pancreatic Cancer Cachexia. PLoS ONE, 2015, 10, e0132786.	1.1	66
335	Validation of Skeletal Muscle Volume as a Nutritional Assessment in Patients With Gastric or Colorectal Cancer Before Radical Surgery. Journal of Clinical Medicine Research, 2017, 9, 844-859.	0.6	14
336	Effect of Megestrol Acetate and Testosterone on Body Composition and Hormonal Responses in COPD Cachexia. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 389-397.	0.5	7

#	Article	IF	Citations
337	Clinical Characteristics of Sarcopenia and Cachexia. Journal of Clinical Nutrition, 2017, 9, 2-6.	0.2	1
338	Home artificial nutrition in advanced cancer patients. Tumori, 2013, 99, 218-24.	0.6	10
340	Stanniocalcin2 acts as an anorectic factor through activation of STAT3 pathway. Oncotarget, 2017, 8, 91067-91075.	0.8	9
341	A novel herbal formula, SGE, induces endoplasmic reticulum stress-mediated cancer cell death and alleviates cachexia symptoms induced by colon-26 adenocarcinoma. Oncotarget, 2018, 9, 16284-16296.	0.8	7
342	Weight gain as a surrogate marker of longer survival in advanced non-small cell lung cancer patients. Annals of Translational Medicine, 2016, 4, 381-381.	0.7	9
343	High-Content Screening of Human Primary Muscle Satellite Cells for New Therapies for Muscular Atrophy/Dystrophy. Current Chemical Genomics, 2013, 6, 21-29.	2.0	13
344	Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice. World Journal of Gastroenterology, 2008, 14, 6303.	1.4	22
345	The Association between Phase Angle of Bioelectrical Impedance Analysis and Survival Time in Advanced Cancer Patients: Preliminary Study. Korean Journal of Family Medicine, 2014, 35, 251.	0.4	44
346	Pentoxifylline treatment in patients with cancer cachexia: A double-blind, randomized, placebo-controlled clinical trial. Advanced Biomedical Research, 2016, 5, 60.	0.2	24
347	An Evaluation of Nutrition Support for Terminal Cancer Patients at Teaching Hospitals in Korea. Cancer Research and Treatment, 2006, 38, 214.	1.3	14
348	The NEAT Predictive Model for Survival in Patients with Advanced Cancer. Cancer Research and Treatment, 2018, 50, 1433-1443.	1.3	21
349	The Influence of Palliative Care on Quality of Life in Patients with Lung Cancer. Materia Socio-medica, 2016, 28, 420.	0.3	7
350	Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy. Annals of Rehabilitation Medicine, 2018, 42, 838-845.	0.6	3
351	The Relationship Between Zinc and Quality of Life in Patients With Upper GI Cancer on Chemotherapy. Journal of the Advanced Practitioner in Oncology, 2017, 8, .	0.2	2
352	The challenges of managing cachexia in advanced cancer. Cancer Nursing Practice, 2009, 8, 24-27.	0.2	7
353	Prospects of 3D Bioprinting as a Possible Treatment for Cancer Cachexia. Journal of Clinical and Experimental Investigations, 2021, 12, em00783.	0.1	0
354	Supportive care. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 709-716.	0.5	0
355	Clues to Tumors: New Concepts of Symptoms, Signs, Syndromes, Paraneoplastic Syndromes, and Predisposition to Ovarian Cancer. , 2003, , 231-269.		2

#	Article	IF	CITATIONS
356	Adrenal Suppression Induced by Megestrol Acetate and the possible protective role of selenium A Histological , Histochemical and Ultrastructural Study. The Egyptian Journal of Hospital Medicine, 2004, 16, 65-91.	0.0	0
360	Appetite Stimulants. , 2005, , 291-302.		1
361	Perspectives and Outlook. , 2005, , 565-569.		0
362	Nutritional Treatment of Cachexia. , 2005, , 267-287.		0
365	KomplementÃ r e Therapieverfahren. , 2006, , 173-369.		0
366	Nutrigenomics and Pharmacogenomics of Human Cancer. Nutrition and Disease Prevention, 2006, , 261-317.	0.1	0
367	Nutrition et traitements du cancer. , 2007, , 769-776.		0
368	Preoperative and Postoperative Nutrition in Hepatobiliary Surgery. , 2007, , 375-385.		0
370	Nutritional Support in Cancer Patients - Physician's View Korean Journal of Clinical Oncology, 2008, 4, 48-55.	0.1	1
371	Nutrition du sujet âgé cancéreux. , 2009, , 207-214.		1
372	Nutrition Support in Cancer. , 2009, , 355-372.		0
375	Overview of the management of the anorexia/weight loss syndrome. , 2009, , 538-545.		0
377	3 Casus 5 Een patiënt met klachten van het maag-darmkanaal 1. , 2010, , 111-128.		0
379	Nutrition and the Host Response to Infection and Injury. , 2010, , 1-20.		0
380	Approaches to Supportive Care. , 2011, , 255-265.		0
381	Best Supportive Care for Palliative Treatment. , 2011, , 665-673.		0
383	Preoperative and postoperative nutrition in hepatobiliary surgery. , 2012, , 391-400.e3.		0
384	Gastric Cancer: A Model to Study Skeletal Muscle Wasting of Cachexia. , 2012, , 215-221.		1

#	Article	IF	CITATIONS
385	Tumorkachexie. , 2012, , 89-97.		0
386	Managing cancer cachexia. , 2012, , 51-72.		1
387	Hubungan Tipe Tumor dengan Tumor Cachexia Syndrome pada Anak. Medica Hospitalia Journal of Clinical Medicine, 2012, 1, .	0.0	0
388	Pengaruh Pemberian Tambahan Putih Telur pada Diet Tinggi Kalori dan Protein terhadap Kadar Albumin Darah Penderita Keganasan Kepala Leher dengan Hipoalbuminemia. Medica Hospitalia Journal of Clinical Medicine, 2013, 1, .	0.0	0
389	A Comparison of the Correlations between the Disgust Sensitivity and Pain-fear Association in Children and Adolescent Patients with Cancer against Non-patient Children and Adolescents. Han'guk Simni Hakhoe Chi Kon'gang = the Korean Journal of Health Psychology, 2013, 18, 869-879.	0.2	0
390	Lipid Metabolism: Stress versus Nonstress States. , 2015, , 53-74.		0
391	Rikkunshito and Ghrelin. Methods in Pharmacology and Toxicology, 2016, , 135-163.	0.1	0
392	Japanese Kampo Medicine: Perspectives. Methods in Pharmacology and Toxicology, 2016, , 237-256.	0.1	0
394	Weight Status and All-Cause Mortality in Older Adults: A Study of Patients With Type 2 Diabetes Undergoing Subtotal Gastrectomy for Cancer. Annals of Geriatric Medicine and Research, 2017, 21, 70-77.	0.7	2
397	Adipose Tissue Remodeling during Cancer-Associated Cachexia: Translational Features from Adipose Tissue Dysfunction. Immunometabolism, 2020, 2, .	0.7	4
399	The Effect of ACE Inhibitor on the Quality of Life amongst Patients with Cancer Cachexia. Asian Pacific Journal of Cancer Prevention, 2020, 21, 325-330.	0.5	3
400	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. American Journal of Cancer Research, 2017, 7, 1107-1135.	1.4	15
401	The Relationship Between Zinc and Quality of Life in Patients With Upper GI Cancer on Chemotherapy. Journal of the Advanced Practitioner in Oncology, 2017, 8, 338-345.	0.2	1
402	Understanding Cachexia in Head and Neck Cancer. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 527-538.	0.7	1
403	Role of Complementary and Alternative Medicine in the Management of Cancer Cachexia. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 539-546.	0.7	0
404	Cachexia Versus Sarcopenia in Clinical Characteristics and Prognostic Value After Radical Gastrectomy for Gastric Cancer: A Large-Scale Prospective Study. Annals of Surgical Oncology, 2022, 29, 2348-2358.	0.7	11
405	Efficacy of resistance training during adjuvant chemotherapy and radiation therapy in cancer care: a systematic review and meta-analysis. Supportive Care in Cancer, 2022, 30, 3701-3719.	1.0	11
406	Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Experimental and Molecular Medicine, 2022, 54, 426-432.	3.2	27

#	Article	IF	CITATIONS
407	Understanding Cachexia in Head and Neck Cancer. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 527-538.	0.7	10
408	Role of Complementary and Alternative Medicine in the Management of Cancer Cachexia. Asia-Pacific Journal of Oncology Nursing, 2021, 8, 539-546.	0.7	6
409	Molecular Mechanisms and Current Treatment Options for Cancer Cachexia. Cancers, 2022, 14, 2107.	1.7	12
410	Inflammation-Based Markers of Nutrition in Cancer Patients. , 0, , .		Ο
411	Home Artificial Nutrition and Energy Balance in Cancer Patients: Nutritional and Clinical Outcomes. Nutrients, 2022, 14, 4307.	1.7	0
412	Role of noncoding RNAs in pancreatic ductal adenocarcinoma associated cachexia. American Journal of Physiology - Cell Physiology, 2022, 323, C1624-C1632.	2.1	1
413	The vital role of arcuate nociceptin/orphanin FQ neurones in mounting an oestradiolâ€dependent adaptive response to negative energy balance via inhibition of nearby proopiomelanocortin neurones. Journal of Physiology, 2022, 600, 4939-4961.	1.3	3
414	Seeking an Important Role on Metabolomics—Effects of β-Estradiol on Lipoprotein Metabolism in Mammary Tumors. Yakugaku Zasshi, 2022, 142, 1191-1199.	0.0	0
415	Are Undernutrition and Obesity Associated with Post-Discharge Mortality and Re-Hospitalization after Hospitalization with Community-Acquired Pneumonia?. Nutrients, 2022, 14, 4906.	1.7	3
416	Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care. Cancers, 2022, 14, 5901.	1.7	5
417	Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nature Reviews Cardiology, 2023, 20, 347-363.	6.1	17
418	Exercise Protocols for Counteracting Cancer Cachexia-Related Declines in Muscle Mass and Strength and the Clinical Assessment of Skeletal Muscle. , 2022, , 215-251.		0
419	Progressive development of melanoma-induced cachexia differentially impacts organ systems in mice. Cell Reports, 2023, 42, 111934.	2.9	2
420	Characterization of a novel dual murine model of chemotherapy-induced oral and intestinal mucositis. Scientific Reports, 2023, 13, .	1.6	5
421	Manejo del sÃndrome caquexia-anorexia en el cáncer avanzado. , 2013, 18, .		0
422	Cannabis sativa. Advances in Medical Diagnosis, Treatment, and Care, 2023, , 1-28.	0.1	Ο
428	Paraneoplastic motor disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 231-250.	1.0	0
437	Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2024, , 239-273.	1.0	0